Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention
- Survival Benefit With Concomitant Oral Platelet Therapy After Coronary Angiography and Before Ad Hoc Percutaneous Coronary Intervention. Patel, Rajan A. G.; White, Christopher J. // Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p978
The authors reflect on the medical research conducted by Gumina and colleagues in the U.S. They note that the group performed an interesting retrospective assessment of the value of an intravenous platelet glycoprotein (GP) IIb/IIIa receptor blocker in addition to dual oral antiplatelet therapy...
- Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Koutouzis, Michael; Lagerqvist, Bo; James, Stefan; Omerovic, Elmir; Matejka, Göran; Grip, Lars; Albertsson, Per // Heart;Sep2011, Vol. 97 Issue 18, p1484
Background: Bivalirudin reduces bleeding events and is associated with a lower mortality than the combination of unfractionated heparin (UFH) and glycoprotein IIb/IIIa inhibitor during primary percutaneous coronary intervention (PCI). However, the effect of adding UFH in patients with ST...
- Deaths associated with platelet glycorprotein llb/llla inhibitor treatment. Brown, D.L. // Heart;May2003, Vol. 89 Issue 5, p535
Background: The glycoprotein (GP) IIb/IIIa inhibitors are potent antagonists of platelet aggregation that are approved to prevent throm and Drug Administration (FDA). Methods: 450 reports of death related to treatment with GP IIb/IIIa inhibitors were submitted to the FDA between 1 November 1997...
- Bird Flu Vaccine Looks Promising. // Internal Medicine Alert;7/15/2008 Pharmacology Watch, p1
The article presents information on various developments related to medicine including vaccine against avian flu developed by Baxter Bioscience, vitamin D for men with heart disease and oral anticoagulant for the treatment of thrombotic complications of hip or knee surgery.
- Researchers Uncover Culprits in Life-Threatening Clotting Disorder. // Trends in Applied Sciences Research;Jul2011, Vol. 6 Issue 7, p775
No abstract available.
- Procoagulants and anticoagulants in fetal blood. A literature survey. Uszyński, Mieczysław; Uszyński, Waldemar; Szymański, Marek // Folia Histochemica et Cytobiologica;2009, Vol. 47 Issue 4, p545
In intrauterine life, hemostasis is maintained by the same components as in extrauterine life (blood platelets, coagulation and fibrinolysis systems, involvement of the vascular wall); in the fetus, however, these components show significant differences of a quantitative/qualitative nature. In...
- Dabigatran may be cost-effective alternative to warfarin in older patients with atrial fibrillation. // Hem/Onc Today;11/25/2010, Vol. 11 Issue 22, p48
The article discusses a study which affirms the link between a high-dose formulation of dabigatran and an increase of more than half a quality-adjusted life year, published in an issue of "Annals of Internal Medicine."
- ERRATUM. // Maedica - a Journal of Clinical Medicine;2007, Vol. 2 Issue 2, p176
Corrections to articles "Oral anticoagulation in clinical practice" and "Autoimmune diseases and infections" that are published in previous issues are presented.
- Risk of Bleeding While Taking Oral Anticoagulants. Sadovsky, Richard // American Family Physician;8/15/2004, Vol. 70 Issue 4, p770
Discusses research being done on the clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Reference to a study by L.A. Linkins et al published in an issue of "Annals of Internal Medicine" journal; Factors being considered in deciding on the...